ERYMAX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erymax, and what generic alternatives are available?
Erymax is a drug marketed by Merz Pharms and is included in one NDA.
The generic ingredient in ERYMAX is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erymax
A generic version of ERYMAX was approved as erythromycin by TORRENT on July 6th, 2020.
Summary for ERYMAX
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 103 |
Patent Applications: | 4,268 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ERYMAX at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for ERYMAX
US Patents and Regulatory Information for ERYMAX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Merz Pharms | ERYMAX | erythromycin | SOLUTION;TOPICAL | 062508-002 | Jul 11, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |